F-031
Fluconazole solution
2.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
About This Item
Formula empirica (notazione di Hill):
C13H12F2N6O
Numero CAS:
Peso molecolare:
306.27
Numero CE:
Numero MDL:
Codice UNSPSC:
41116107
ID PubChem:
NACRES:
NA.24
Prodotti consigliati
Grado
certified reference material
Livello qualitativo
Stato
liquid
Caratteristiche
(Snap-N-Spike®)
Confezionamento
ampule of 1 mL
Produttore/marchio commerciale
Cerilliant®
Concentrazione
2.0 mg/mL in methanol
tecniche
gas chromatography (GC): suitable
liquid chromatography (LC): suitable
applicazioni
clinical testing
Formato
single component solution
Temperatura di conservazione
−20°C
InChI
1S/C13H12F2N6O/c14-10-1-2-11(12(15)3-10)13(22,4-20-8-16-6-18-20)5-21-9-17-7-19-21/h1-3,6-9,22H,4-5H2
RFHAOTPXVQNOHP-UHFFFAOYSA-N
Cerchi prodotti simili? Visita Guida al confronto tra prodotti
Descrizione generale
Fluconazole, sold under trade names such as Trican, Monicure, Diflucan®, and Afungil, is an antifungal drug used in the treatment and prevention of superficial and systemic fungal infections. This Certified Spiking Solution® is suitable as starting material for calibrators, controls, or linearity standards for therapeutic drug monitoring or clinical and diagnostic testing of fluconazole in patient blood, serum, or plasma samples by HPLC or LC-MS/MS.
Applicazioni
- Gas chromatography-mass spectrometry determination of conjugated linoleic acids and cholesterol oxides and their stability in a model system.: This study employs the Equity-5 Capillary GC Column to determine conjugated linoleic acids and cholesterol oxides, demonstrating the column′s effectiveness in analyzing complex lipid matrices and its utility in ensuring precision and reliability in food chemistry and nutritional analysis (Yen et al., 2010).
- Comparison of series 5 gas chromatography column performances from a variety of manufacturers for separation of chlorinated dibenzo-p-dioxins and dibenzofurans using high-resolution mass spectrometry.: This research compares the performance of various series 5 GC columns, including the Equity-5 Capillary GC Column, for analyzing persistent organic pollutants. The study underscores the column′s efficiency in environmental analytics, particularly in the separation of complex mixtures of hazardous organic compounds (Fishman et al., 2004).
Note legali
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Diflucan is a registered trademark of Pfizer, Inc.
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Prodotti correlati
N° Catalogo
Descrizione
Determinazione del prezzo
Avvertenze
Danger
Indicazioni di pericolo
Consigli di prudenza
Classi di pericolo
Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1
Organi bersaglio
Eyes,Central nervous system
Codice della classe di stoccaggio
3 - Flammable liquids
Classe di pericolosità dell'acqua (WGK)
WGK 2
Punto d’infiammabilità (°F)
49.5 °F - closed cup
Punto d’infiammabilità (°C)
9.7 °C - closed cup
Scegli una delle versioni più recenti:
Certificati d'analisi (COA)
Lot/Batch Number
Ci dispiace, ma al momento non ci sono COA disponibili online per questo prodotto.
Se ti serve aiuto, non esitare a contattarci Servizio Clienti
Possiedi già questo prodotto?
I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.
I clienti hanno visto anche
Maria I Rosa et al.
European journal of obstetrics, gynecology, and reproductive biology, 167(2), 132-136 (2013-01-03)
To investigate the efficacy, compared to placebo, of fluconazole 150 mg weekly, given for six months as prophylaxis against recurrent vulvovaginal candidiasis (RVVC). A quantitative systematic review was performed, and randomized controlled trials were included. We conducted searches at Medline
Candida albicans prosthetic hip infection in elderly patients: is fluconazole monotherapy an option?
Theodoros Kelesidis et al.
Scandinavian journal of infectious diseases, 42(1), 12-21 (2010-01-09)
The increasing numbers of joint arthroplasties being undertaken, and the increase in patients with systemic illnesses undergoing the procedure, have contributed to a continuing increase in prosthetic joint infections. Candida prosthetic joint infection is a rare clinical entity, and only
M C Ethier et al.
British journal of cancer, 106(10), 1626-1637 (2012-05-10)
Objectives were to compare systemic mould-active vs fluconazole prophylaxis in cancer patients receiving chemotherapy or haematopoietic stem cell transplantation (HSCT). We searched OVID MEDLINE and the Cochrane Central Register of Controlled Trials (1948-August 2011) and EMBASE (1980-August 2011). Randomised controlled
Jenny Wan Sai Cheong et al.
Medical mycology, 51(3), 261-269 (2012-09-20)
With the widespread use of long-term fluconazole prophylaxis and suppressive treatment, the potential development of fluconazole resistance poses a threat to the management of cryptococcal disease. Interpretive breakpoints for the in vitro antifungal susceptibility testing of C. neoformans have not
K Turner et al.
Current medicinal chemistry, 19(27), 4617-4620 (2012-08-11)
Invasive candidiasis (IC) in the premature infant population is a common infection that results in substantial morbidity and mortality. For these patients, fluconazole is among the first line therapies to treat and prevent IC, and yet few prospective studies investigating
Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..
Contatta l'Assistenza Tecnica.